Search Results for “Merck” – media

Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan

November 21, 2024 07:30 Author: Du Sumin Source: Time Weekly 1 In just one week, two business development (BD) transactions with a total transaction amount exceeding 20 billion yuan have made innovative pharmaceutical company Lixin Pharmaceutical the focus of attention in the industry. On November 20th, China Biopharmaceutical (01177.HK, hereinafter referred to as “Zhongsheng Pharmaceutical”) announced that it had signed an equity investment and strategic cooperation agreement with Lixin Pharmaceutical. Accordingly, with an investment of 142 million yuan, Sinopharm will acquire 4.91% of the equity of Lixin Pharmaceutical. At the same time, it will reach strategic cooperation in Chinese Mainland on the LM-108 monoclonal antibody targeting CCR8 independently developed by Lixin Pharmaceutical, and has the right to choose multiple double antibody or ADC innovative drugs in the research pipeline of Lixin Pharmaceutical for cooperation. The specific terms will be otherwise agreed. This is the second BD transaction conducted by Lixin ...
- Source: drugdu
- 39
- November 22, 2024
The first day of the national negotiations | Antiviral, anesthetic, antihypertensive drugs, etc. are being discussed! Hengrui, Hisense, Merck…appeared

On October 27, the 2024 National Medical Insurance Negotiations officially began at the National People’s Congress Conference Center in Beijing. The entrance to the venue was crowded. Some companies said that “the talks will not start until tomorrow, but we came in advance to check out the atmosphere.” This year, a total of 162 generic drugs will participate in the negotiations/bidding. The negotiations will be conducted by 25 negotiation experts from medical insurance departments selected from all over the country and divided into 5 groups. The negotiations will last until October 30, and the final results are expected to be announced in November. It is reported that the varieties of negotiations on the first day involve antiviral, anesthetic analgesic, antihypertensive and other fields. Hengrui, Merck, Kangyuan, Zhengda Tianqing, Renfu, Hisense, Xinlitai, Daiichi Sankyo, Baxter and other companies have entered the venue. Companies on the scene revealed that their Chinese medicine ...
- Source: drugdu
- 73
- October 29, 2024
Merck’s first GMP grade cell culture medium production line in China has been commercialized and put into operation

Merck, a globally leading technology company, announced on July 12th that it has successfully commercialized its first GMP grade cell culture medium (CCM) production line in China. Merck has invested approximately 6.6 million euros in its manufacturing base located in Nantong, an industrial hub in the Yangtze River Delta region, in an effort to meet the growing demand in the Chinese market for high-quality customized cell culture media (used in fields such as biopharmaceuticals, vaccines, and new therapies). This localized commercial production can enable Chinese customers to reliably and efficiently obtain Merck’s highly reputable customized cell culture medium products and services. With its rich and professional formula experience and knowledge, Merck can produce high-quality customized cell culture media and innovative solutions based on specific formulas, ensuring batch uniformity and production efficiency of products. Merck Life Sciences China Managing Director Wu Bo said, “This investment further expands Merck’s business territory and ...
- Source: drugdu
- 108
- September 30, 2024
Daiichi Sankyo, Merck Launch Phase III Trial Evaluating Safety, Efficacy of Ifinatamab Deruxtecan in Patients with Relapsed Small Cell Lung Cancer

By Don Tracy, Associate Editor IDeate-Lung02 will compare ifinatamab deruxtecan to a physician’s choice of chemotherapy in patients with relapsed small cell lung cancer. Daiichi Sankyo and Merck have commenced the IDeate-Lung02 Phase III clinical trial, which aims to compare the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) vs. physician’s choice of chemotherapy in patients with relapsed small cell lung cancer (SCLC) following disease progression with only one prior line of platinum-based chemotherapy. According to both companies, the initiation of the trial was based on results from a subgroup analysis of the IDeate-PanTumor01 Phase I/II trial of ifinatamab deruxtecan, which was presented at the 2023 World Conference on Lung Cancer.1 “Patients living with small cell lung cancer face poor outcomes with currently available treatments,” said Mark Rutstein, MD, global head, oncology clinical development, Daiichi Sankyo, in a press release. “The IDeate-Lung02 trial is an important next step as we ...
- Source: drugdu
- 91
- August 3, 2024
Merck Sharp & Dohme Animal Health Completes Acquisition of Leyland Animal Health Aquatic Business

Rowe, NJ, USA, July 9, 2024 – Merck Sharp & Dohme (Merck is the corporate trading name of Merck & Co. of Rowe, NJ, USA) announced today that its Animal Health division has completed the acquisition of the aquatic business of Gift Blue Animal Health. The acquisition strengthens Merck Sharp & Dohme Animal Health’s position in the aquaculture industry, enabling it to promote fish health, welfare and sustainability across all aspects of aquaculture, conservation and fisheries. Rick DeLuca, President of Mercer Animal Health, said: “With the completion of this acquisition, we are well positioned in the aquaculture industry with a strong and comprehensive portfolio of products covering warm water aquaculture, cold water aquaculture, vaccines, antiparasitic treatments, water conditioners and nutritional supplements. We are excited to welcome our new colleagues to Merck Sharp & Dohme Animal Health and look forward to working together towards our shared goal of ‘Science for Healthier ...
- Source: drugdu
- 87
- July 15, 2024
Merck opens $195.7m expanded distribution centre in Germany

German science and technology company Merck KGaA has announced the opening of its expanded Life Science distribution centre at Schnelldorf, which involved an investment of €180m ($195.7m). With this investment, the facility has almost doubled in size, adding 25,000m² to its area. The development bolsters the company’s capacity to meet the surging global demand for critical drugs and contribute to public health significantly. The newly expanded site now features a manual down-filling operation and an extra distribution area for a wide array of products destined for laboratories and research institutions worldwide. The Schnelldorf centre’s workforce comprises 470 specialists including engineers, and manufacturing and distribution experts. The site expansion is part of the company’s multi-year investment programme in the life science business sector. The company has announced projects worth more than €2bn since 2020. They span Europe, China and the US, reflecting the company’s strategic focus on enhancing industrial capacity and ...
- Source: drugdu
- 81
- June 7, 2024
Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition

Merck’s EyeBio acquisition brings a lead program ready for pivotal testing in diabetic macular edema. The therapy could pose competition to Eylea, the blockbuster Regeneron Pharmaceuticals eye drug. By Frank VinluanMerck is on the hunt for drugs with blockbuster potential to make up for declining revenue when its top product, the cancer immunotherapy Keytruda, loses patent protection in the next few years. The pharmaceutical giant is getting a contender through the acquisition of a clinical-stage startup whose lead program is on track to begin pivotal testing in diabetic macular edema. According to deal terms announced Wednesday, Merck is acquiring Eyebiotech Limited, or EyeBio, for $1.3 billion in cash up front. Shareholders of the New York-based company could receive up to $1.7 billion more in milestone payments. EyeBio develops drug for retinal conditions in which inflammation leads to the breakdown of the inner blood-retinal barrier. This breakdown leads to vascular leakage, ...
- Source: drugdu
- 101
- June 1, 2024
Merck KGaA announces its largest investment in Asia

Merck KGaA Darmstadt Germany announced its largest investment in Asia through a ceremony of its € 300 million Bioprocessing Production Center in Daejeon, South Korea. The new facility will accelerate the biotech and pharmaceutical industry’s development by manufacturing vaccines, cell and gene therapies, and protein-based therapies. Once completed, the investment aims to create as many as 300 new jobs and continue to grow and support global demand for critical drugs and therapies. The ceremony witnessed the presence of the leadership team of Merck including Matthias Heinzel- CEO of the Life Science business, Karen Madden- Chief Technology Officer, Life Science business, Sebastián Arana- Head, Process Solutions, Life Science business, Ivan Donzelot- Head of Integrated Supply Chain Operations. They were joined by Cheong Inkyo, Trade Minister of Korea, Lee Jang Woo, Mayor of Daejeon, Ambassador Georg Schmidt along with other dignitaries and partners.
- Source: drugdu
- 90
- May 31, 2024
Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck

Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody’s target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi.Immunology and inflammation continues to be one of the hottest areas for research, and investment firm Blackstone is joining in with the launch of Uniquity Bio, a new startup whose lead asset from Merck addresses a clinically validated target that puts it in direct competition with some big pharmaceutical companies. Uniquity is backed by up to $300 million in financing from Blackstone Life Sciences, the firm’s biotechnology investment division. The in-licensed Merck drug, solrikitug, is ready to begin Phase 2 development in its lead indications, chronic obstructive pulmonary disease (COPD) and asthma. The Uniquity pipeline includes a third undisclosed gastrointestinal indication. Solrikitug is a monoclonal antibody designed to block thymic stromal lymphoprotein ...
- Source: drugdu
- 79
- May 17, 2024
Merck plans €300m investment at new German research centre

Merck KGaA (Merck) has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at its global headquarters in Darmstadt, Germany. Set to open in 2027, the centre will be a hub for developing biopharmaceuticals, including antibodies and messenger ribonucleic acid applications. The investment is part of Merck’s broader €1.5bn commitment to the Darmstadt site by 2025. Covering an area of 18,000m², the Advanced Research Center will consolidate efforts on key life science technologies such as the production of antibodies, recombinant proteins, and viral vectors. It allows collaboration across departments of the company in an open, modern work environment. The facility will also focus on the advancement of cell culture media, pharmaceutical formulation, purification aids, and analytical chromatography. Merck said the new centre will support both European and global customers in addressing significant medical challenges. Merck CEO and executive board chair Belén Garijo said: “With ...
- Source: drugdu
- 109
- April 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.